Abstract
Background Kidney injury is common in COVID-19 infection, but serum creatinine (SCr) is not a sensitive or specific marker of kidney injury. We hypothesized that molecular markers of tubular injury could diagnose COVID-19 associated kidney damage and predict its clinical course.
Methods This is a prospective cohort study of 444 consecutive COVID-19 patients (43.9% females, 20.5% African American, 54.1% Latinx) in Columbia University’s Emergency Department at the peak of the New York pandemic (March-April 2020). Urine and blood were collected simultaneously at admission (median time of day 0, IQR 0-2 days) and within 1 day of a positive SARS-CoV-2 test in 70% of patients. Biomarker assays were blinded to clinical data.
Results Urinary NGAL (uNGAL) was strongly associated with AKI diagnosis (267±301 vs. 96±139 ng/mL, P=1.6×10−10). uNGAL >150ng/mL had 80% specificity and 75% sensitivity to diagnose AKIN stage 2 or higher. uNGAL quantitatively predicted the duration of AKI and outcomes, including death, dialysis, shock, and longer hospital stay. The risk of death increased 73% per standard deviation of uNGAL [OR (95%CI): 1.73 (1.29-2.33), P=2.8×10−4] and was independent of baseline SCr, co-morbidities, and proteinuria [adjusted OR (95%CI): 1.51 (1.10-2.11), P=1.2×10−2]. Proteinuria and uKIM-1 also indicated tubular injury but were not diagnostic of AKI. Typically, distal nephron segments transcribe NGAL, but in COVID-19 biopsies with widespread acute tubular injury (ATI), NGAL expression overlapped KIM-1 in proximal tubules.
Conclusion uNGAL predicted diagnosis, duration, and severity of AKI and ATI, as well as hospital stay, dialysis, shock, and death in patients with acute COVID-19.
Competing Interest Statement
Columbia University owns and licensed patents involving NGAL to Bioporto and Abbott.
Funding Statement
K. Xu is supported by NIH-NIDDK T32 Research in Nephrology Training Grant (5T32DK108741-05). K. Kiryluk, J. Barasch, N. Shang, S. Kudose, and V. D'Agati are supported by the NIH-NIDDK's Kidney Precision Medicine Project (4UH3DK114926-03). S. Mohan and J. Stevens are supported by NIH-NIDDK (R01-126739). Columbia CTSA is funded by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873. The funders had no role in formulating the hypotheses, collecting or analyzing samples, interpretation of data or the preparation and revision of the manuscript and datasets. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or Columbia University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Columbia University Biobank COVID-19 studies were reviewed and approved by the Columbia University Medical Center Institutional Review Board (IRB). Samples and tissues were collected and stored in the Columbia University COVID-19 Biobank in accordance with the Institutional Review Board of Columbia University protocol (IRB AAAS7370) while the study of kidney injury biomarkers was approved by the IRB AAAS7948. A subset of patients was included under a public health crisis IRB waiver of consent specifically for COVID-19 studies if patients were deceased, not able to consent, or if the study team was unable to contact them as per the Columbia Institutional Review Board protocols. Mice were utilized according to the Institutional Animal Care and Use Committee (AC-AAAY7464) and adhere to NIH Guide for the Care and Use of Laboratory Animals. Our study was reported according to STROBE guidelines for cohort studies.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data analyses and results are described in this article and supplementary files.
